News

Biscayne Neurotherapeutics has licensed the Chinese rights to its investigative antiepileptic therapy BIS-001ER to Global Drug Development Centre (GDCC) China in Taiwan, China, Hong Kong, and Macau. Biscayne is developing BIS-001ER to treat refractory forms of focal epilepsy, including catastrophic pediatric-onset epilepsies such as Dravet syndrome and Lennox Gastaut. “BIS-001ER is…

Raising a child with Dravet syndrome is hard enough without the added stress of fighting with insurance companies to cover the expensive medications such kids need to stay alive. Beth Fox ought to know. Her 9-year-old daughter, Brenna, has Dravet — a rare, catastrophic, lifelong form of drug-resistant epilepsy that…

An RNA splicing technique that Stoke Therapeutics is developing led to the production of a protein that’s lacking in Dravet syndrome, a study in mice showed. Stoke discussed the approach at the Oligonucleotide & Peptide Therapeutics Conference in Boston, March 26-28. Dr. Charles R. Allerson, Stoke’s vice president of chemistry, delivered the…

Noninherited genetic mutations affecting the SCN1A gene may help explain almost 1% of Dravet syndrome cases of unknown cause, according to researchers from Japan. Genetic disorders are commonly inherited from parents who are carriers of the abnormal gene variant that cause the disease. If the disease is recessive, it means the…

Epidiolex, GW Pharmaceuticals’ investigational cannabis-based oral therapy, was proven safe in a Phase 2 clinical trial testing it in young children with Dravet syndrome. The therapy is a plant-derived cannabidiol being developed for patients with treatment-resistant forms of epilepsy including…

GW Pharmaceuticals announced that it recently received allowance notices from the U.S. Patent and Trademark Office (USPTO) for five new patent applications for Epidiolex (cannabidiol). Three of these applications specifically focus on methods to reduce the frequency of seizures in patients with a form of Dravet syndrome. Notices of allowance…

Genetic sequencing and the speed with which it can help diagnose a child’s disease — in addition to revealing the genes that cause at least half of the 7,000 rare diseases currently known — was the focus of a discussion by three top New York geneticists. The Feb. 28 conference,…

Increased brain levels of a protein involved in inflammation were found to suppress seizures in mice, a finding that may have potential for the treatment of types of epilepsy, including Dravet syndrome. The study, “Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the…

When it comes to rare diseases, one that definitely makes the list is spinal muscular atrophy with respiratory distress — SMARD,  for short. Hunter Pageau, a 12-year-old boy from North Haven, Connecticut, is one of only 80 people in the world known to have SMARD, a motor neuron disease…

In his 10 months on the job, Commissioner Scott Gottlieb of the U.S. Food and Drug Administration is earning praise for his efforts to make clinical trials for new therapies more flexible and responsive to the needs of rare disease patients. From cystic fibrosis to epidermolysis bullosa, the FDA…